JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $385,000 | +39.0% | 8,422 | +35.8% | 0.00% | +33.3% |
| Q3 2017 | $277,000 | +52.2% | 6,202 | +2.2% | 0.00% | +50.0% |
| Q2 2017 | $182,000 | +184.4% | 6,069 | +109.3% | 0.00% | +100.0% |
| Q1 2017 | $64,000 | +100.0% | 2,900 | +70.6% | 0.00% | – |
| Q4 2016 | $32,000 | -69.2% | 1,700 | -50.6% | 0.00% | -100.0% |
| Q3 2016 | $104,000 | +2.0% | 3,444 | +29.9% | 0.00% | 0.0% |
| Q2 2016 | $102,000 | +10.9% | 2,651 | +9.5% | 0.00% | 0.0% |
| Q1 2016 | $92,000 | -15.6% | 2,420 | -2.0% | 0.00% | 0.0% |
| Q4 2015 | $109,000 | +12.4% | 2,470 | +2.9% | 0.00% | 0.0% |
| Q3 2015 | $97,000 | +24.4% | 2,400 | +65.5% | 0.00% | +100.0% |
| Q2 2015 | $78,000 | -79.7% | 1,450 | -77.1% | 0.00% | -85.7% |
| Q1 2015 | $385,000 | +73.4% | 6,337 | +49.1% | 0.01% | +40.0% |
| Q4 2014 | $222,000 | – | 4,250 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |